A Recombinant DNA Plasmid Encoding the sIL-4R-NAP Fusion Protein Suppress Airway Inflammation in an OVA-Induced Mouse Model of Asthma

Inflammation

Volumn 39, Issue 4, 2016, Pages 1434-1440

  Liu, Xin ^a   Fu, Guo ^a,c   Ji, Zhenyu ^b   Huang, Xiabing ^a   Ding, Cong ^a   Jiang, Hui ^a   Wang, Xiaolong ^a   Du, Mingxuan ^a   Wang, Ting ^a   Kang, Qiaozhen ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Academy of Medical and Pharmaceutical Sciences   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

asthma; HP NAP; sIL 4R; Th1 Th2

Indexed keywords

ANTIASTHMATIC AGENT; BACTERIAL PROTEIN; IMMUNOGLOBULIN E; INTERLEUKIN 4 RECEPTOR; NEUTROPHIL-ACTIVATING PROTEIN A, HELICOBACTER PYLORI; RECOMBINANT DNA; RECOMBINANT PROTEIN;

ANIMAL; ASTHMA; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION; MOUSE; OVUM; PLASMID; STANDARDS; TH1 TH2 BALANCE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BACTERIAL PROTEINS; DNA, RECOMBINANT; IMMUNOGLOBULIN E; INFLAMMATION; MICE; OVUM; PLASMIDS; RECEPTORS, INTERLEUKIN-4; RECOMBINANT PROTEINS; TH1-TH2 BALANCE;

EID: 84970002455     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-016-0375-6     Document Type: Article

References (32)

1. Tillie-Leblond, I., D. Montani, B. Crestani, J. de Blic, M. Humbert, M. Tunon-de-Lara, A. Magnan, N. Roche, J. Ostinelli, and P. Chanez. 2009. Relation between inflammation and symptoms in asthma. Allergy 64(3): 354–367.
2. Liu, J., Y. Cheng, X. Zhang, X. Zhang, S. Chen, Z. Hu, C. Zhou, E. Zhang, and S. Ma. 2015. Astragalin attenuates allergic inflammation in a murine asthma model. Inflammation 38(5): 2007–2016.
3. Bosnjak, B., B. Stelzmueller, K.J. Erb, and M.M. Epstein. 2011. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respiratory Research 12(114).
4. Chung, K.F. 2015. Targeting the interleukin pathway in the treatment of asthma. Lancet 386(9998): 1086–1096.
5. Finkelman, F.D., S.P. Hogan, G.K.K. Hershey, M.E. Rothenberg, and M. Wills-Karp. 2010. Importance of cytokines in murine allergic airway disease and human asthma. Journal of Immunology 184(4): 1663–1674.
6. Borish, L.C., H.S. Nelson, M.J. Lanz, L. Claussen, J.B. Whitmore, J.M. Agosti, and L. Garrison. 1999. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine 160(6): 1816–1823.
7. Maes, T., G.F. Joos, and G.G. Brusselle. 2012. Targeting interleukin-4 in asthma: lost in translation? American Journal of Respiratory Cell and Molecular Biology 47(3): 261–270.
8. Steinke, J.W., and L. Borish. 2001. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respiratory Research 2(2): 66–70.
9. Henderson, W.J., E.Y. Chi, and C.R. Maliszewski. 2000. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. Journal of Immunology 164(2): 1086–1095.
10. Borish, L.C., H.S. Nelson, J. Corren, G. Bensch, W.W. Busse, J.B. Whitmore, and J.M. Agosti. 2001. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. The Journal of Allergy and Clinical Immunology 107(6): 963–970.
11. Aryan, Z., S.T. Holgate, D. Radzioch, and N. Rezaei. 2014. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. International Archives of Allergy and Immunology 164(1): 46–63.
12. Xiao, H.T., Z. Liao, L. Chen, and R.S. Tong. 2012. A promising approach for asthma treatment by multiwayly modulating toll-like receptors. European Review for Medical and Pharmacological Sciences 16(15): 2088–2091.
13. D’Elios, M.M., A. Amedei, A. Cappon, G. Del Prete, and M. de Bernard. 2007. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunology and Medical Microbiology 50(2): 157–164.
14. Cappon, A., C. Babolin, D. Segat, L. Cancian, A. Amedei, F. Calzetti, M.A. Cassatella, M.M. D’Elios, and M. de Bernard. 2010. Helicobacter pylori-derived neutrophil-activating protein increases the lifespan of monocytes and neutrophils. Cellular Microbiology 12(6): 754–764.
15. Amedei, A. 2006. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. The Journal of Clinical Investigation 116(4): 1092–1101.
16. Fu, H. 2014. Helicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications. World Journal of Gastroenterology 20(18): 5294–5301.
17. Codolo, G., P. Mazzi, A. Amedei, P.G. Del, G. Berton, M.M. D’Elios, and M. de Bernard. 2008. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cellular Microbiology 10(11): 2355–2363.
18. Lee, J.J., D. Dimina, M.P. Macias, S.I. Ochkur, M.P. McGarry, K.R. O’Neill, C. Protheroe, R. Pero, T. Nguyen, S.A. Cormier, E. Lenkiewicz, D. Colbert, L. Rinaldi, S.J. Ackerman, C.G. Irvin, and N.A. Lee. 2004. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305(5691): 1773–1776.
19. Newcomb, D.C., and R.S. Peebles. 2013. Th17-mediated inflammation in asthma. Current Opinion in Immunology 25(6): 755–760.
20. Jiang, H., X. Wu, H. Zhu, Y. Xie, S. Tang, and Y. Jiang. 2015. FOXP3(+)Treg/Th17 cell imbalance in lung tissues of mice with asthma. Int J Clin Exp Med 8(3): 4158–4163.
21. Shi, Y.H., G.C. Shi, H.Y. Wan, L.H. Jiang, X.Y. Ai, H.X. Zhu, W. Tang, J.Y. Ma, X.Y. Jin, and B.Y. Zhang. 2011. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with allergic asthma. Chinese Medical Journal 124(13): 1951–1956.
22. Durrant, D.M., and D.W. Metzger. 2010. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunological Investigations 39(4–5): 526–549.
23. Liang, S.C., A.J. Long, F. Bennett, M.J. Whitters, R. Karim, M. Collins, S.J. Goldman, K. Dunussi-Joannopoulos, C.M. Williams, J.F. Wright, and L.A. Fouser. 2007. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. Journal of Immunology 179(11): 7791–7799.
24. Olin, J.T., and M.E. Wechsler. 2014. Asthma: pathogenesis and novel drugs for treatment. BMJ 349(10): g5517.
25. Bice, J.B., E. Leechawengwongs, and A. Montanaro. 2014. Biologic targeted therapy in allergic asthma. Annals of Allergy, Asthma & Immunology 112(2): 108–115.
26. Beasley, R., A. Semprini, and E.A. Mitchell. 2015. Risk factors for asthma: is prevention possible? Lancet 386(9998): 1075–1085.
27. Wegmann, M. 2009. Th2 cells as targets for therapeutic intervention in allergic bronchial asthma. Expert Review of Molecular Diagnostics 9(1): 85–100.
28. Hansbro, P.M., G.V. Scott, A.T. Essilfie, R.Y. Kim, M.R. Starkey, D.H. Nguyen, P.D. Allen, G.E. Kaiko, M. Yang, J.C. Horvat, and P.S. Foster. 2013. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opinion on Investigational Drugs 22(1): 49–69.
29. D’Elios, M.M., G. Codolo, A. Amedei, P. Mazzi, G. Berton, G. Zanotti, G. del Prete, and M. de Bernard. 2009. Helicobacter pylori, asthma and allergy. FEMS Immunology and Medical Microbiology 56(1): 1–8.
30. Linden, A., and B. Dahlen. 2014. Interleukin-17 cytokine signalling in patients with asthma. The European Respiratory Journal 44(5): 1319–1331.
31. McGuirk, P., S.C. Higgins, and K.H. Mills. 2010. The role of regulatory T cells in respiratory infections and allergy and asthma. Current Allergy and Asthma Reports 10(1): 21–28.
32. Sehrawat, A., S. Sinha, and A. Saxena. 2015. Helicobacter pylori neutrophil-activating protein: a potential Treg modulator suppressing allergic asthma? Frontiers in Microbiology 6(493).